Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Clinical Data
  • AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data
  • Clinical Data

AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data

BioSpace

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

Clinical DataRead full story

pharminent April 21, 2026 (Last updated: April 21, 2026)

BioSpace

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

Clinical DataRead full story

Post navigation

Previous: MSD, Eisai report setback in first-line kidney cancer trial
Next: Novo Nordisk preps filings for sickle cell drug etavopivat

Related Stories

  • Clinical Data

Novo Nordisk starts trialing lower maintenance doses of oral Wegovy

pharminent August 21, 2026
  • Clinical Data

Cancer vaccine win restores Wall Street’s faith in Moderna

pharminent August 20, 2026
  • Clinical Data

New Taiho, Cullian data heats up lung cancer drug battle

pharminent August 13, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.